In This Issue
Canada’s Excessive Pricing Regulations Survive Another Constitutional Challenge
The Patented Medicine Prices Review Board (the PMPRB) commenced a proceeding against Alexion Pharmaceuticals Inc. (Alexion) in respect of Alexion’s drug, SOLIRIS (eculizumab), which is used to treat rare and devastating blood and genetic conditions. The PMPRB claimed and successfully argued that Alexion was selling Soliris at an excessive price, under sections 82 and 85 of the Patent Act.
Health Canada Announces Random Testing of Medical Cannabis for Prohibited Pest Control Product Use
In an announcement earlier today, Health Canada advised that it will be conducting random testing of medical cannabis products produced by licensed producers.
Have Your Say on Federal Food Regulatory Change: Consultation Open On Draft Safe Food For Canadian Regulations
In January 2017, draft regulations under the Safe Food For Canadians Act (which was passed in November 2012) were published.
To Engage or Not to Engage: Guidance on Motions to Strike a Within Application
The Federal Court has reaffirmed and clarified how a pharmaceutical brand company should respond to a generic company’s motion to strike an application for abuse of process under s. 6(5)(b) of the Patented Medicines (Notice of Compliance) Regulations.
January 2017 Deal Round-Up
The following is a summary of major deals in the life science space that closed or were announced as closed in January 2017. Vancouver-based Quark Venture Inc., through its Global Health Sciences Venture Fund, continued to be an active investor, with investments made both in Canada and the United States in the month of January 2017.
Canada’s Cannabis Opportunity in the Era of Trump
Although the United States government’s attitudes toward cannabis have eased in recent years, the election of President Donald Trump has generated renewed uncertainty surrounding the future of the U.S. cannabis market. Canada, conversely, will very likely soon be one of the first industrialized countries with fully legalized recreational and medical cannabis, and investment in the Canadian cannabis market has been unprecedented.
Proposed Changes in Personal Use Importation of Pest Control Products
Earlier this week, Health Canada announced proposed changes to the Pest Control Products Regulations that would limit the ability of individuals to import unregistered pesticides for personal use.